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  20 
Abstract  21 
Urogenital Chlamydia trachomatis infection is the most common sexually transmitted bacterial 22 
infection throughout the world. While progress has been made to better understand how type 23 
strains develop and respond to environmental stress in vitro, very few studies have examined 24 
how clinical isolates behave under similar conditions. Here, we examined the development and 25 
persistence phenotypes of several clinical isolates, to determine how similar they are to each 26 
other, and the type strain C. trachomatis D/UW-3/Cx. The type strain was shown to produce 27 
infectious progeny at a higher magnitude than each of the clinical isolates, in each of the six 28 
tested cell lines. All chlamydial strains produced the highest number of infectious progeny at 44 29 
h PI in the McCoy B murine fibroblast cell line, yet showed higher levels of infectivity in the 30 
MCF-7 human epithelial cell line. The clinical isolates were shown to be more susceptible than 31 
the type strain to the effects of penicillin and iron deprivation persistence models in the MCF-7 32 
cell line. While subtle differences between clinical isolates were observed throughout the 33 
experiments conducted, no significant differences were identified. This study reinforces the 34 
importance of examining clinical isolates when trying to relate in vitro data to clinical outcomes, 35 
as well as the importance of considering the adaptations many type strains have to being cultured 36 
in vitro.     37 
  38 
Introduction 39 
Chlamydia trachomatis is an obligate intracellular pathogen and is the most common bacterial 40 
sexually transmitted infection (STI) worldwide. There are more than 83,000 Chlamydia 41 
infections recorded in Australia each year (1). The pathology and sequelae associated with 42 
chlamydial diseases are thought to be associated with the infected individual’s inflammatory 43 
response and potentially influenced by a number of important host factors (2). In women, 44 
chlamydial disease ranges from mild cases of cervicitis, endometritis and salpingitis, to more 45 
serious cases of pelvic inflammatory disease (PID), tubal infertility, and life-threatening ectopic 46 
pregnancy (3-5).  47 
Cases of urogenital Chlamydia are treated with either azithromycin or doxycycline. While 48 
evidence suggests doxycycline (usually 7 day regimen) is slightly more effective at clearing 49 
infection, 1g single-dose azithromycin is often prescribed for its simple one-off treatment dose 50 
(6, 7). Azithromycin is a broad-spectrum macrolide antibiotic with a relatively long half-life (40 51 
- 68 h), high lipid solubility, and accumulates within macrophages migrating to the site of 52 
infection (8, 9). Despite its high efficacy, instances do occur in which monitored women remain 53 
infected after treatment. The reasons for this remain unclear, but potential explanations include; 54 
reinfection from an untreated partner, chlamydial gastrointestinal colonization and auto-55 
inoculation of the cervical site or treatment failure (10, 11). Direct macrolide resistance is 56 
generally not considered a probable cause due to the antibiotic’s mechanism of action, and the 57 
scarcity of clinical isolates with validated genotypic or phenotypic resistance to azithromycin 58 
(12-16). Furthermore, mutants created in vitro with single nucleotide polymorphisms (SNPs) in 59 
their 23S rRNA and L4 protein-encoding genes show poor biological fitness and viability (17-60 
20), further supporting their emergence in the population is likely to be rare. 61 
When combined, in vitro and clinical evidence suggests that C. trachomatis rarely survives 62 
treatment, which likely reflect both the pathogen and its intracellular niche. One candidate 63 
mechanism is chlamydial persistence, which is believed to be a positive and beneficial adaptation 64 
unique to the genus Chlamydia (21, 22). The persistence phenotype is characterised by several 65 
reversible morphological, transcriptional and metabolic changes (23-27). The collective profiles 66 
of these changes vary depending on the inducer of persistence; however, the morphologically-67 
aberrant chlamydial cells observed during persistence, altered inclusion sizes and the reversible 68 
loss of both cultivability and replicative capacity are the universal hallmarks of chlamydial 69 
persistence (reviewed (28)).  70 
Several environmental conditions and exogenous stimuli have been demonstrated to induce 71 
chlamydial persistence in vitro (29). Penicillin and IFN-γ are two of the most extensively studied 72 
of these stimuli, and have both been used to characterise different aspects of the persistence 73 
phenotype, as reviewed by Wyrick (30). Use of the iron-chelating agent deferoxamine mesylate 74 
has shown that iron restriction not only induces persistence in C. trachomatis, but also alters the 75 
pathogen’s signaling pathways that modulate host-cell apoptosis (31, 32). Interestingly, IFN-γ 76 
also decreases cellular levels of iron in infected cells by downregulating their transferrin receptor 77 
expression (33).  78 
Previous investigations into chlamydial persistence have established that type strains have 79 
variations in their degree of responsiveness to certain stimuli, and have altered susceptibilities to 80 
antibiotics while in the persistent state (34-37). In the present study, we examined the in vitro 81 
phenotypes of selected clinical isolates of C. trachomatis isolated during the Australian 82 
Chlamydia Treatment Study (ACTS)(11). Their relative abilities to infect and develop in 83 
different cell lines were measured, as were their responses to two widely used and 84 
physiologically relevant models of in vitro chlamydial persistence. Their susceptibility to 85 
azithromycin during persistence was also investigated, to better understand whether persistence 86 
has implications for treatment with frontline antibiotics when analysed on recent clinical isolates.  87 
 88 
Methods 89 
Cell culture and cultivation of Chlamydia 90 
McCoy B, MCF-7, CACO-2, HeLa, SiHa, and ARPE-19 cell lines (details in Table 1) were 91 
cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10 % vol vol-1 fetal 92 
calf serum (FCS; Sigma), 4 mM analyl-glutamine (Sigma), 100 μg ml-1 streptomycin (Life 93 
Technologies) and 50 μg ml-1 gentamicin (Life Technologies). A range of cell types available to 94 
the study were selected to profile any possible differences in the clinical isolates. All cell lines 95 
were incubated at 37 ˚C in a humid environment containing 5% CO2. All cell lines were 96 
regularly confirmed to be free of Mycoplasma contamination using either an in-house PCR, or 97 
the Mycoalert™ Plus Mycoplasma Detection Kit assay (Lonza). All six clinical isolates used 98 
were obtained from the Australian Chlamydia Treatment Study (ACTS). This was a cohort study 99 
of women diagnosed with and treated for genital Chlamydia (11) to examine factors associated 100 
with repeat chlamydia infection. In one case, two isolates from one participant after a repeat 101 
positive event were included in the study in the event that they prove to have some detectable 102 
difference in persistence phenotypes to analysed here. Isolates were collected from infected 103 
women using swabs stored in a 2 ml cryovial tube containing a sucrose-phosphate glutamate 104 
(SPG) buffer, at -80˚C, and couriered on dry ice. A unique code has been generated to identify 105 
each isolate purely for the purposes of this paper. 106 
 107 
Isolates were cultured from the original cervical swabs from women using a series of culture 108 
steps to attain sufficient culture for these experiments (6 to12 passages depending on the isolate). 109 
Stocks were stored and propagated from sucrose phosphate glutamate (SPG) buffer which 110 
consisted of 5 mM glutamic acid, 10 mM sodium phosphate, 250 mM sucrose balanced to pH 111 
7.4. The five clinical isolates used in this study are shown in Table 2. 112 
 113 
 114 
Table 1. Mammalian cell lines used in this study 
Name Cell Type Origin ATCC® Code (™) 
McCoy B Fibroblast Fibroblast from Mus musculus CRL-1696 
MCF-7 Epithelial Human mammary epithelium    HTB-22 
CACO-2 Epithelial Human colorectal adenocarcinoma HTB-37 
HeLa Epithelial Human cervical carcinoma CRM-CCL-2 
SiHa Epithelial Human cervical squamous cell carcinoma  HTB-35 
ARPE-19 Epithelial Human adult retinal pigmented epithelium CRL-2302 
    






600 (1) K Repeat infection, first detection 
600 (13) K Repeat infection, second detection 
Infectivity and determination of viable progeny 115 
McCoy B, MCF-7, CACO-2, HeLa, SiHa and ARPE-19 cells were cultured in 96-well plates, in 116 
triplicates for each condition and experimental analysis conducted. Cells were infected with each 117 
of the five clinical isolates and type strain D/UW-3/Cx at a multiplicity of infection (MOI) of 118 
0.5. Cultures were immediately centrifuged at 500 × g and 37° C for 30 minutes, then incubated 119 
under standard conditions (37° C, 5% CO2). At 4 hours post infection (h PI), the infectious media 120 
in each well was replaced with complete DMEM supplemented with 1 µg ml-1 cycloheximide 121 
before further incubation. To determine the infectivity of the isolates in each cell line cultures 122 
were fixed with 100% methanol at 30 h PI for evaluation by immunofluorescence and 123 
microscopy. Infectious progeny counts (inclusion forming units) of each isolate was determined 124 
from cultures harvested at 44 and 54-hour time points of infection. Inclusion forming units were 125 
determined by serially dilutions of stocks from each of the harvested cultures onto fresh cultures 126 
of McCoy B cells, which were fixed at 30 h PI for evaluation by immunocytochemistry. 127 
ompA genotyping 128 
DNA was extracted from the original swab samples collected (as per the ACTS study protocol) 129 
were swirled in 500 μl of PBS solution. A 200 μl aliquot of the swab/PBS homogenate was 130 
extracted using the MagNA Pure 96 (Roche Applied Science, Germany) automated system, 131 
according to the manufacturer’s instructions and utilizing the MagNA Pure 96 DNA and Viral NA 132 
Small Volume Kit, and eluted in 100μl in MagNA Pure 96 elution buffer(11).  133 
620 (1) D No repeat infection 
628 (1) E No repeat infection 
649 (1) K No repeat infection, genotypically close to 600 (1) 
   
All C. trachomatis genotype determinations utilized a 5μl aliquot of PBS swab homogenate 134 
elution, utilizing a series of qPCR amplification assays targeting the ompA gene of C. trachomatis 135 
as described previously (38).  136 
 137 
Penicillin and iron deprivation persistence models 138 
Persistence models were conducted in MCF-7 cells.  2.5 x 104 MCF-7 cell monolayers cultured 139 
for 24 h were infected at multiplicity of infection (MOI) 0.8 (slighly higher than the previous 140 
cultures due to expected loss of some organisms in the persistence model). Cultures were 141 
immediately centrifuged at 500 × g and 37° C for 30 minutes, then incubated under standard 142 
conditions (37° C, 5% CO2, 95% air). At 4 h post infection (h PI), the infectious media in each 143 
well was replaced with complete DMEM supplemented with 1 µg ml-1 cycloheximide as well as 144 
0, 0.02, 0.05, or 1.0 U ml-1 benzylpenicillin (Pen G). 2,2’-Bipyridyl (Bpdl) was used in 145 
accordance with the methods previously outlined by Thomson and Carabeo (doses of –400M) 146 
(39). Cultures were incubated until 44 h PI, where they were harvested stocked in SPG for 147 
analysis of inclusion forming units, or washed and media replaced with fresh media without the 148 
penicillin or supplemented with FeCl3 until 96 or 110 h PI of culture and stocked in SPG. The 149 
infectious yield of all cultures at each of the time points was determined by infecting serial 150 
dilutions of stored stocks into monolayers of McCoy B cells using the standard protocol and 151 
cultures were fixed with methanol at approximately 30 h PI, before immunocytochemistry and 152 
visualisation by fluorescence microscopy. Cultures for infectivity yields were routinely 153 
conducted in 96 or 48 well plates, replicate cultures were conducted in 24 well plates on top of 154 
1.5mm coverslips for the cases where fixing, immunocytochemistry and imaging by microscopy 155 
to eludicate phenotype was part of the experiment. Azithromycin treatment was conducted to 156 
determine each isolates MICs using the methodology previously outlined (40), each isolates MIC 157 
dose was then used to treat the isolate during and in the absence of the persistence inducing 158 
conditions to evaluate if the isolate’s capacity to survive the antibiotic treatment at the MIC 159 
changed by being in persistence.    160 
Immunofluorescence microscopy 161 
Cultures were fixed with methanol, permeabilized with triton X-100 (0.5%) in Dulbecco’s 162 
phosphate-buffered saline (dPBS) and blocked with 1% bovine serum albumin (BSA) in dPBS 163 
overnight. Once blocked, cultures were then further incubated with dPBS containing 4’,6-164 
diamino-2-phenyindole (DAPI; 1/40,000) and rabbit sera (1/500) containing antibodies raised 165 
against the C. trachomatis high-temperature requirement A (HtrA) protein for 1 h at room 166 
temperature (antibody and protocol previously described (41, 42)). Following this, cultures were 167 
washed four times with dPBS containing 0.2% tween 20, and then incubated with dPBS 168 
containing an Alexa Fluor 488-conjugated goat anti-rabbit antibody (1/600; Thermo Fisher 169 
Scientific) for 45 minutes at room temperature. The stained cultures were then washed five times 170 
more with the dPBS tween solution. Cultures on 13 mm (No. 1.5) coverslips were stained and 171 
labelled using the same process, with the addition of a mouse anti-α-tubulin (1/500; Thermo 172 
Fisher Scientific) in the first antibody incubation, and an Alexa Fluor 546-conjugated goat anti-173 
mouse antibody (1/600; Thermo Fisher Scientific) in the second incubation. Stained coverslips 174 
were mounted to clear glass slides using n-propyl gallate (NPG) and sealed using clear varnish 175 
around the edge of the coverslip. Stained and labelled plate cultures were visualized and imaged 176 
using the Nikon Eclipse Ti-S fluorescent microscope or the GE InCell 3000 high-throughput 177 
fluorescent microscope. Coverslips were visualized and imaged using the Nikon Eclipse Ti-E 178 
confocal microscope.  179 
Data analysis and graphing 180 
Raw data was compiled using Microsoft Excel 2010 before being transferred into GraphPad 181 
Prism version 8.0.0 for Windows for statistical analysis and graphing with each value and any 182 
applicable statistical testing described in the respective figure legends.  183 
 184 
Results 185 
Clinical isolates differed in  infectivity and growth more profoundly than the differences 186 
caused by the cell lines 187 
Six cell lines were selected, to compare how susceptible they were to infection by four of the 188 
clinical isolates, and type strain D/UW-3/Cx (Fig 1.). The human mammary epithelial cell line 189 
(MCF-7) was found to result in the highest cell infection levels after exposure to the chlamydial 190 
strains for each of the four clinical isolates, with 35-40% of all counted cells becoming infected. 191 
Both the retinal cell line (ARPE-19) and cervical carcinoma cell line (SiHa) were observed to 192 
have the lowest percentage of infectivity (5-10%) for all four clinical isolates, while the type 193 
strain was observed to still have produced inclusions in 25-30% in both these lines. The proposed 194 
0.5 infectivity or MOI was calculated from an ifu/ml yield in McCoy B cells. While the type 195 
strain showed a similar level of infectivity across the McCoy B, MCF-7, HeLa and SiHa lines, it 196 
did show slightly lower levels in CACO-2 and ARPE-19. The same six cell lines used for the 197 
infectivity assay were infected and harvested at two timepoints, to determine the number of 198 
infectious progeny that had been produced during the developmental period. All four isolates 199 
produced the most infectious progeny (IFU ml-1) in the McCoy B cell line (Fig. 1). For example, 200 
clinical isolate 600(1) grown in McCoy B cells yielded 1.2x106 at 44 h PI, while in HeLa cells, it 201 
yielded 3.7x104 IFU ml-1. Similarly, the type strain produced higher levels of progeny in the 202 
McCoy B cells (9.8x106), in CACO-2 (9.4x106), and HeLa cells (7.1x106), compared to MCF-7 203 
(1.1x106), SiHa (1.9x106) cells, and ~100-fold fewer in ARPE-19 cells (5.9x104). The ARPE-19 204 
cell line was also shown to produce the least number of infectious progeny for clinical isolates, 205 
with all four showing no detectable progeny. Less variation in the infectivity and infectious 206 
progeny production from each of the clinical isolates was observed in the SiHa cell lines 207 




Figure 1. Infectivity and infectious progeny yield in different cell types for the clinical 212 
isolates. The figure shows the inclusion forming units yielded (left y axis) from each isolate 213 
(orange indicates yields at 44 h PI and blue indicates yields at 54 h PI) and the % infectivity at 30 214 
h PI (right y axis, green bar). Each cell line analysed includes A: McCoy B, B: Hela, C: MCF-7, 215 
D: SiHa, E: APRE-19, and F: CACO2. The bars for IFU ml-1 include a total of n=27 216 
representative images to determine the mean of a minimum of n=3 separate experimental 217 
replicates, shown with standard deviation. The bars for % infectivity are representative of n= 9 218 
experimental replicates. The data is shown from a single experiment, and is consistent with other 219 
attempts at the experiment. 220 
 221 
Clinical isolates show similar susceptibilities to conditions of iron deprivation at lower 222 
doses than type strain D/UW-3/Cx 223 
In order to more closely examine if persistence phenotypes were impacted by ompA genotypes, 224 
and the known outcomes in participants in the ACTS trial an additional isolate was included in 225 
these persistence experiments to have a close genotype to the isolate from a participant that 226 
experienced repeat infection. Five clinical isolates and the type strain were cultivated in MCF-7 227 
cells, treated with 100, 200 (D/UW-3/Cx only) and 400 µM bipyridal (Bpdl) ± 100 µM iron as 228 
FeCl3, with infectious progeny determined at 96 h PI. As seen in Fig. 2A, the type strain was 229 
able to recover from up to 100 µM of Bpdl (7.1x104 IFU ml-1 before recovery) with the 230 
supplementation of FeCl3 into culture (3.1x10
8 IFU ml-1 after recovery). The five clinical isolates 231 
showed lower recovery, even from at lowest dose of Bpdl, as seen in Fig. 2. For example (Fig. 232 
2C), at the 100 µM dose of Bpdl with and without recovery, 600(13) yielded 3.1x103 and 7.0x102 233 
IFU ml-1 (near the limit of detection for this assay) respectively. All five isolates produced 234 
infectious progeny in a manner that was dose-dependent, with slightly lower levels of infectious 235 
progeny present in cultures treated with 400 µM than those treated with 100 µM.  236 
  237 
 238 
 239 
Figure 2. Iron deprivation related persistence and recovery of the clinical isolates. The 240 
graphs show the infectious progeny produced by type strain D/UW-3/Cx (A) and five clinical 241 
isolates (B: 600(1); C: 600(13); D: 1-020(1); E: 628(1); F: 649 (1)) in MCF-7 cells treated with 242 
Bpdl ± 100 µM iron as FeCl3 for recovery. Each bar represents the mean of three experimental 243 
replicates analysed using n=10 separate fields of view from n=3 experimental replicates with 244 
error bars showing the standard error of the mean (SEM). Data was analysed by way of a 3-way 245 
ANOVA using GraphPad Prism version 8.0.0 for Windows. Significant differences are indicated 246 
by **** p<0.0001. The data is shown from a single experiment, and is consistent with other 247 
attempts at the experiment. 248 
 249 
Treatment with azithromycin during iron deprivation-induced persistence decreases the 250 
number of recoverable infectious progeny among clinical isolates 251 
Each of the five clinical isolates and the type strain were cultured in MCF-7 cells treated with 252 
Bpdl, subsequently treated with azithromycin (Az), and then recovered with supplementation of 253 
iron. The azithromycin dose used was the MIC that had been determined for each isolate. The 254 
MICs were as follows: 600 (1): 0.032 g/ml, 600 (13): 0.125 g/ml, 620: 0.032 g/ml, 628: 255 
0.064 g/ml; 649: 0.064 g/ml, and D/UW-3/Cx: 0.064 g/ml. All strains showed a significant 256 
decrease in infectious progeny at 44 h PI when treated with azithromycin, Bpdl, or both (Fig. 3, 257 
p<0001). Compared to the untreated control at 44 h PI (5.4x105 IFU ml1), D/UW-3/Cx showed 258 
an impaired ability to recover from the effects of Bpdl when also treated with azithromycin 259 
(2.9x104 IFU ml-1), even with iron supplementation (5.0x102 IFU ml-1). Compared to their 260 
respective untreated controls at 44 h PI (Fig. 3), all five clinical isolates were found to have only 261 
slight differences in their resulting infectious yield when treated with the combinations of 262 
azithromycin, Bpdl, and FeCl3. For example, the untreated control 600(13) culture produced 263 
2.2x104 compared to only 1.5x103 IFU ml-1 after treatment and recovery. Analysis of the cultures 264 
by confocal microscopy showed morphologies consistent with persistence, as inclusions visible 265 
were consistent with persistence after treatment with penicillin; and regular development after 266 





Figure 3. Iron deprivation induced persistence and recovery of the chlamydial isolates. 272 
Infectious progeny (inclusion forming units, y axis) produced by the type strain D/UW-3/Cx (A) 273 
and five clinical isolates (B: 600(1); C: 600(13); D: 620 (1); E: 628(1); F: 649(1)) in MCF-7 cells 274 
treated with Bpdl, Az, ± 100 µM iron as FeCl3 for recovery. Azithromycin dose was the MIC for 275 
the strain; 600 (1): 0.032 g/ml, 600 (13): 0.125 g/ml, 620: 0.032 g/ml, 628: 0.064 g/ml; 276 
649: 0.064 g/ml, and D/UW-3/Cx: 0.064 g/ml. Each bar represents the mean of three 277 
experimental replicates analysed using n=10 separate fields of view from n=3 subsequent 278 
infectivity (passage) wells with error bars showing the standard error of the mean (SEM). Data 279 
was analysed by way of a 3-way ANOVA using GraphPad Prism version 8.0.0 for Windows. 280 
Significant differences are indicated by **** p<0.0001, and * p=0.0138. The data is shown from 281 




Figure 4. Confocal microscopy of Chlamydia cultures during iron-deprivation persistence. 286 
MCF7 cells infected with 620 (1) (top two rows) or type strain D/UW-3/Cx (bottom two rows) 287 
were fixed and visualised using immunofluorescence. Active and persistent inclusions containing 288 
chlamydial HtrA appears as green, while the host alpha-tubulin appears as red and the host cell 289 
nucleus as blue. This images are representatives of observations for each experimental condition. 290 
 291 
Clinical isolates entered persistence at lower doses of penicillin compared to the type strain  292 
Several doses of penicillin were used to induce persistence in each strain, which was confirmed 293 
by measuring viability before and after recovery from the drug. The data shown in Fig. 5 294 
demonstrates that compared to the untreated controls at 44 h PI, the addition of 0.02 U ml-1 295 
penicillin slightly impacted the development of each clinical isolate, while the 0.05 U ml-1 and 296 
1.0 U ml-1 doses had rendered them non-cultivable. Conversely, only the 1.0 U ml-1 dose caused 297 
the type strain to enter persistence, with far less pronounced effects than the clinical isolates 298 
prevalent at the lower doses. 600(1) and 600(13) produced 2.1x106 and 5.5x105 IFU ml-1 in their 299 
respective untreated cultures, compared to 6.6x105 and 8.7x104 IFU ml-1 in the cultures treated 300 
with the lowest dose of penicillin. The type strain exhibited only slightly impacted growth at 301 
both the lower doses (5.0x107 IFU ml-1 untreated versus 4.1x106 and 9.4x104 at 0.02 and 0.05, 302 
respectively), and only became non-cultivable at the 1.0 U ml-1 dose. Each of the five clinical 303 
isolates and the type strain were able to produce detectable (after recovery) infectious progeny by 304 
110 h PI, all to a similar level, even after treatment with 1 U ml-1 of penicillin. Confocal 305 
microscopy examination of the morphology of the cultures confirmed the presence of visible 306 
forms consistent with persistent or recovered morphology (Fig. 6). Specifically, at 44 and 110 h 307 
PI and in the absence of penicillin, each of the five clinical isolates and the type strain showed 308 
typical morphologies consistent with regular development. At the same time point, cultures 309 
treated with penicillin showed significantly smaller inclusions with enlarged particles inside, 310 
morphologies consistent with persistence. Imaging of the cultures at 110 h PI (66 hours after the 311 






Figure 5. Enumeration of infectious progeny from penicillin persistence experiments. 318 
Inclusion forming units from culture harvested at 44 and 110 h PI are shown on the graph(s). The 319 
inclusion forming units per ml (y axis, log scale), and dose of Penicillin (x axis), and recoverable 320 
inclusion forming units per ml at 44 h PI (blue bars- during persistence), and 110 h PI (red bars - 321 
recovery). Data shown represents the mean value of n=3 separate experimental replicates wells 322 
with n=10 images analysed from each of n=3 wells, with error bars representative of the SEM. 323 
The data is shown from a single experiment and is consistent with other attempts at the 324 
experiment. This data was used to select the dose of penicillin G for the next experiments for 325 





Figure 6. Confocal microscopy of the chlamydial cultures in presence and absence of 331 
penicillin and post recovery. Active and persistent inclusions containing Chlamydial HtrA 332 
appears as green, while the host alpha-tubulin appears as red and the host cell nucleus as blue. 333 
This images are representatives of observations for each experimental condition. 334 
 335 
Clinical isolates treated with azithromycin during penicillin persistence showed a dose-336 
dependent decrease in recoverable infectious progeny 337 
To assess whether clinical isolates had altered susceptibilities to azithromycin during persistence, 338 
three clinical isolates and D/UW-3/Cx were cultured in MCF-7 cells and treated with both 339 
penicillin and azithromycin. Persistence was induced using 0.05 U ml-1 of penicillin for the three 340 
clinical isolates and 1.0 U ml-1 for the type strain. At 44 h PI, Fig 7 shows a complete loss of 341 
infectious progeny for the penicillin-treated cultures, which was recoverable (albeit reduced) by 342 
110 h PI. The infectious progeny of the four strains at 44 h PI was also observed to decrease by 343 
up to 100-fold lower when treated with azithromycin alone. In the type strain, this effect was also 344 
seen, whereby the recoverable infectious progeny decreased in the presence of azithromycin 345 
only, with a complete loss of viability at 44 h PI when both azithromycin and penicillin were 346 
added. Although no statistical differences were apparent for any isolates treated with 347 
azithromycin during penicillin persistence. It appeared that the recovery of the clinical isolates 348 
from persistence was further reduced when treated with azithromycin at the MIC, with two of the 349 
isolates (600(13) and 649) appearing to be more impacted by the combination treatment. 350 
 351 
 352 
Figure 7. Impact of azithromycin treatment during penicillin induced persistence. The 353 
graphs show the IFU/ml of each clinical isolate and type strain D/UW-3/Cx in the presence of 354 
azithromycin (at the minimum inhibitory concentration (MIC) for that strain), with and without 355 
pretreatment and recovery from benzylpenicillin. Azithromycin dose; 600 (1): 0.032 g/ml, 600 356 
(13): 0.125 g/ml, 620: 0.032 g/ml, 628: 0.064 g/ml; 649: 0.064 g/ml, and D/UW-3/Cx: 357 
0.064 g/ml. The X axis shows each isolate grouped at both time points on the left- and right-358 
hand sides respectively and the Y axis shows infectivity of the cultures as IFU ml-1. Data shown 359 
represents the mean value of n=3 separate experimental replicate wells with an average of n=10 360 
images analysed to input the result for each of n=3 wells, with error bars representative of the 361 
SEM. The data is shown from a single experiment, although is consistent with other attempts at 362 
the experiment. The p values for the significant different outcomes for the isolates are as follows 363 
(left to right): 0.043, 0.099, 0.066, 0.027, 0.0066). 364 
 365 
Discussion 366 
The susceptibility and growth permissiveness of different cell lines to infection by C. 367 
trachomatis enables examination of the host-pathogen relationship (43-46). Such studies 368 
frequently find differences between strains in their ability to enter the host cell, and complete 369 
their developmental cycle (47). The infectivity of the clinical isolates in the present study was 370 
observed to be highest in the MCF-7 cell line, despite the long-standing practice throughout the 371 
field of using McCoy or HeLa cells for cultivation and isolation of C. trachomatis, especially 372 
from clinical samples (48-50). However, the infectious yields were highest in the McCoy B cell 373 
line for each of the strains tested. The ARPE-19 cell line was observed to have a very low 374 
susceptibility to infection by, and permissiveness of growth to all strains except D/UW-3/Cx, yet 375 
was nonetheless able to be infected by each of the strains, even though it is not an epithelial cell 376 
type. The inability to detect progeny from this cell line for the clinical isolates may reflect the 377 
low yields being below detection of the assay, or that the clinical isolates in these cells are unable 378 
to form infectious elementary bodies. Overall, these findings reinforce that there are phenotypic 379 
differences between type strains and clinical isolates that likely reflects the adaptation of D/UW-380 
3/Cx to growth in vitro (51).  381 
Although it has been shown that type strains of C. trachomatis have varying levels of 382 
susceptibility to the in vitro effects of IFN-γ, fewer studies have examined how different strains 383 
respond to penicillin or iron deprivation (52). In this study, we aimed to determine how clinical 384 
isolates respond to such conditions. Both were selected on the basis that penicillin has been used 385 
widely as a chlamydial persistence model so our findings can be interpreted in light of other 386 
studies (37, 53-55); while iron deprivation is potentially a more clinically relevant model when 387 
considering the physiology of the female reproductive tract (56-58). Penicillin is known to 388 
induce persistence by interacting with chlamydial penicillin-binding proteins (PBPs), while host 389 
cell-derived iron is essential for chlamydial development. Both points combined, raise the 390 
possibility that genetic variation among infecting strains could result in differing thresholds at 391 
which they divert from the regular developmental cycle into persistence.  392 
To assess the susceptibility of each strain to penicillin, they were treated with a dose range in 393 
MCF-7 cells. None of the clinical strains showed any notable difference in their levels of 394 
susceptibility to penicillin persistence, with all entering a viable but non-cultivable state at 0.05 395 
U ml-1 of the antibiotic. In contrast, the type strain D/UW-3/Cx remained cultivable up to the 396 
maximum dose used, which was 1 U ml-1. A recent study into the effects of beta-lactam 397 
antibiotics on C. trachomatis showed that type strain E/UW-3/Cx entered persistence at 0.02 U 398 
ml-1 of benzylpenicillin (37). Although using different host cells, this suggests there may be 399 
different susceptibilities among type strains.  400 
 401 
Similarly, there were no large observed differences in the responses of clinical isolates to the 402 
effects of iron deprivation. In a recent review, Pokorzynski and colleagues postulated a complex 403 
system by which C. trachomatis may be able to both passively and actively acquire ferrous and 404 
ferric iron from within the host cytoplasm by modulating the hosts own iron trafficking pathways 405 
(59). As with other instances of chlamydial persistence, it is possible that strain differences may 406 
in turn result in slight differences in the proteins that conduct these functions.  407 
The effects of azithromycin were tested on a selection of clinical isolates during both active and 408 
persistent development. We observed no differences in the susceptibilities of active and 409 
persistent infections, in any of the clinical strains tested. Previous findings by the Caldwell group 410 
demonstrate that during IFN-γ-mediated persistence, a serovar D type strain of C. trachomatis is 411 
significantly more susceptible to azithromycin (60). However, Wyrick and Knight have shown 412 
that a serovar E type strain is less susceptible to the same antibiotic during penicillin-mediated 413 
persistence (53). This reinforces previous findings that different inducers of persistence produce 414 
different phenotypes (61), which likely reflects the physiological stress the inducer places upon 415 
C. trachomatis.  416 
Collectively these findings show that clinical isolates respond to the effects of penicillin, iron 417 
deprivation, and azithromycin in a similar but more pronounced way than type strain D/UW-418 
3/Cx. This is important because these are recent clinical isolates, indicating that persistence may 419 
occur more frequently and with lower thresholds in vivo. Here we demonstrated that clinical 420 
isolates showed subtle variation in thresholds for persistence that may be more distinct and 421 
impactful in the complex in vivo environment. These variations may translate into phenotypes in 422 
vivo that could relate to heterogenic survival of antibiotic treatment, or different capacities to 423 
survive in different tissue niches (e.g. rectal compared to urogenital) that could be relevant for 424 
future investigation of chlamydial variation.  425 
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